Meyer-Losic F - Search Results

1

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.

Awasthi N, Schwarz MA, Zhang C, Klinz SG, Meyer-Losic F, Beaufils B, Thiagalingam A, Schwarz RE. Awasthi N, et al. Among authors: meyer losic f. Mol Cancer Ther. 2022 Jul 5;21(7):1149-1159. doi: 10.1158/1535-7163.MCT-21-0860. Mol Cancer Ther. 2022. PMID: 35500018 Free PMC article.

2

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer.

Barbier S, Beaufils B, de Miguel R, Reyre M, Le Meitour Y, Lortie A, de Boisferon MH, Chaumeron S, Espirito A, Fossati L, Lagarde P, Klinz S, Thiagalingam A, Lezmi S, Meyer-Losic F. Barbier S, et al. Among authors: meyer losic f. Oncol Ther. 2023 Mar;11(1):111-128. doi: 10.1007/s40487-022-00215-2. Epub 2023 Jan 16. Oncol Ther. 2023. PMID: 36645622 Free PMC article.

3

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA. Meyer-Losic F, et al. PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305. eCollection 2013. PLoS One. 2013. PMID: 24324595 Free PMC article.

4

DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.

Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, Dubois V, de Coupade C, Boukaissi M, Chéné AS, Tranchant I, Arranz V, Zoubaa I, Fruchart JS, Ravel D, Kearsey J. Meyer-Losic F, et al. Clin Cancer Res. 2008 Apr 1;14(7):2145-53. doi: 10.1158/1078-0432.CCR-07-4580. Clin Cancer Res. 2008. PMID: 18381956

5

Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.

Nakhlé J, Pierron V, Bauchet AL, Plas P, Thiongane A, Meyer-Losic F, Schmidlin F. Nakhlé J, et al. Among authors: meyer losic f. Oncoimmunology. 2016 Feb 18;5(6):e1145333. doi: 10.1080/2162402X.2016.1145333. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471612 Free PMC article.

6

Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [¹⁷⁷Lu]Lu-Satoreotide Tetraxetan and the Agonist [¹⁷⁷Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST₂-Positive Tumours.

Plas P, Limana L, Carré D, Thiongane A, Raguin O, Mansi R, Meyer-Losic F, Lezmi S. Plas P, et al. Among authors: meyer losic f. Pharmaceuticals (Basel). 2022 Aug 30;15(9):1085. doi: 10.3390/ph15091085. Pharmaceuticals (Basel). 2022. PMID: 36145306 Free PMC article.

7

On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models.

Savel H, Barbier S, Proust-Lima C, Rondeau V, Thiébaut R, Meyer-Losic F, Richert L. Savel H, et al. Among authors: meyer losic f. Cancer Res Commun. 2023 Jan 26;3(1):140-147. doi: 10.1158/2767-9764.CRC-22-0238. eCollection 2023 Jan. Cancer Res Commun. 2023. PMID: 36968232 Free PMC article. Clinical Trial.

8

Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.

Guilbaud N, Kraus-Berthier L, Meyer-Losic F, Malivet V, Chacun C, Jan M, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman J, Pierré A. Guilbaud N, et al. Clin Cancer Res. 2001 Aug;7(8):2573-80. Clin Cancer Res. 2001. PMID: 11489841

9

Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).

Meyer-Losic F, Quinonero J, Dubois V, Alluis B, Dechambre M, Michel M, Cailler F, Fernandez AM, Trouet A, Kearsey J. Meyer-Losic F, et al. J Med Chem. 2006 Nov 16;49(23):6908-16. doi: 10.1021/jm0606591. J Med Chem. 2006. PMID: 17154520

10

Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.

Ravel D, Dubois V, Quinonero J, Meyer-Losic F, Delord J, Rochaix P, Nicolazzi C, Ribes F, Mazerolles C, Assouly E, Vialatte K, Hor I, Kearsey J, Trouet A. Ravel D, et al. Clin Cancer Res. 2008 Feb 15;14(4):1258-65. doi: 10.1158/1078-0432.CCR-07-1165. Clin Cancer Res. 2008. PMID: 18281561

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters